Intended Use Statement Analysis
Intended Use Statement analysis helps Regulatory Affairs Teams and Quality Assurance Teams evaluate device purpose, classification indicators, risk indicators, and QMS dependencies before early FDA pathway and QMS scoping decisions.
What Regulatory Teams Can Decide From This Analysis
Is device purpose clearly defined?
Identify whether the Intended Use Statement defines device purpose, intended users, use environment, clinical role, and responsible owner, so teams can confirm review scope before pathway planning.
Where could evidence risk appear?
Spot ambiguous claims, weak clinical context, conflicting software signals, outdated positioning, or traceability gaps before they create submission risk, approval delay, or audit exposure.
Can teams make a clearer pathway decision?
Evaluate whether the Intended Use Statement provides enough evidence, detail, and references for Regulatory Affairs, Quality Assurance, and Product teams to revise, escalate, or submit with confidence.
How Teams Use This Analysis
Regulatory Affairs Teams and Quality Assurance Teams use Intended Use Statement analysis to review intended-use language more consistently, catch regulatory scoping risk earlier, and turn claims into decisions about pathway planning and QMS readiness.
Intended Use Analysis
Maps intended purpose and intended user type into a clearer review position, helping product teams understand scope boundaries before design planning.
Clinical Claims Review
Checks whether claims and regulatory impact signals hold together, reducing the chance that teams rely on weak rationale.
Information Gap Analysis
Organizes open scoping questions and reviewer notes into a practical follow-up path, so unresolved issues can be addressed before they become approval blockers.
QMS Planning
Connects device characteristics to QMS scope, giving teams a clearer basis for validation planning and documentation scoping work.
Regulatory Pathway Mapping
Surfaces classification signals, predicate cues, and pathway indicators, giving regulatory reviewers earlier visibility into strategy risk before Intended Use Statements reach submission planning.
SaMD Classification Check
Turns scattered software language into structured findings, helping review teams prioritize classification questions, evidence needs, and escalation paths.
Key Intended Use Statement Insights to Look For
Automatan organizes Intended Use Statement evaluation into structured insights that help teams judge classification coverage, regulatory alignment, QMS readiness, and the quality of the evidence behind pathway decisions.
Document Name
Source title is captured to maintain document traceability and avoid version confusion across all regulatory scoping review cycles.
Device Name
The device or system name provides a consistent anchor for insights, ensuring the analysis stays linked to the correct medical device or digital health system.
Device Description
A structured summary of functional role, clinical context, and operational behavior gives teams immediate context without scope misinterpretation.
Device Purpose
Extracted intended purpose signals distinguish explicit commitments from implied intent, helping teams focus regulatory scoping planning where it matters most.
Diagnostic/Therapeutic Decisions
Classification of diagnostic versus therapeutic influence clarifies which FDA review lens applies and directs early evidence collection.
Life Support
Flags life-support association to highlight elevated regulatory scrutiny and prioritize review efforts.
Invasiveness
Determines invasive or non-invasive status to guide risk assignment and control expectations.
Active Device
Active versus non-active designation informs the correct FDA framework and classification reasoning.
Duration of Use
Transient, short-term, or long-term use signals shape classification thinking and monitoring priorities.
Biological Effect
Interaction with biological tissue or physiological systems is identified, ensuring higher-risk device characteristics are properly scoped.
Patient Population
Pediatric, adult, or mixed population signals provide clarity on intended use scope and regulatory relevance.
Anatomical Location
Automated extraction of anatomical context, such as cardiovascular or neurological use, informs classification thinking and evidence requirements.
Device Class
Directional device class signals offer early insight for FDA pathway planning.
Device Type
Device category and clinical role anchor classification reasoning and support product-family mapping.
Intended User Type
Identifies clinician, patient, or caregiver users to guide usability, labeling, and training considerations.
User Skill Requirements
Required training signals inform validation planning and human factors study design.
Intended Use Environment
Deployment context, including hospital, clinic, home, or emergency settings, ensures risk alignment with actual operating conditions.
Claims & Clinical Assertions
Automatan compiles performance, workflow, clinical benefit, and automation claims to highlight potential evidence-scrutiny areas.
Regulatory Impact of Claims
Mapping claim implications guides prioritization of supporting documentation and ensures evidence requirements are addressed early.
Device Characteristics
Technical and operational traits, including connectivity, reusability, and automation, affect QMS planning and validation.
Who Uses This Analysis
Intended Use Statement review pulls in several stakeholders at once. Each group needs a different cut of the same document, focused on the regulatory questions closest to its mandate.
Regulatory Affairs leadership
Reads Intended Use Statements for classification signals, using the analysis to decide whether pathway planning needs escalation.
Quality Assurance leadership
Reviews likely QMS artifact coverage, helping the team identify documentation gaps before quality planning.
Product and Engineering teams
Uses the analysis to compare intended functionality against design intent, giving stakeholders a clearer basis for product scoping.
Medical Device Startups & Founders
Targets positioning risk and follow-up needs, turning the document review into a realistic messaging revision list.
Clinical & Pre-Submission Review Teams
Assesses the evidence sensitivity to determine whether the statement supports pre-submission review.
How Intended Use Statement Analysis Connects to Your Regulatory Workflow
Automatan works inside the tools regulatory teams already use. Intended Use Statements and supporting files can be imported from common document sources and turned into structured scoping intelligence without rebuilding the regulatory process.
Google Drive
Import documents directly from Google Drive so Automatan can extract classification signals and risk indicators from files already stored by the team.
Add AI Integration
Google Docs
Analyze Intended Use Statements stored in Google Docs without moving files, enabling seamless extraction of regulatory insights within the existing workspace.
Add AI Integration
OneDrive
Access documents from OneDrive so teams in regulated environments can capture pathway signals directly from their repository.
Add AI Integration
Dropbox
Pull intended-use statements from Dropbox to turn embedded claims, software signals, and information gaps into structured scoping intelligence inside Automatan.
Add AI IntegrationAnalyze Intended Use Statements With Clearer Regulatory Evidence
Regulatory Affairs Teams and Quality Assurance Teams need more than claims. Automatan helps teams analyze Intended Use Statements for classification indicators, QMS readiness, and follow-up actions, so every review leads to clearer regulatory decisions.